{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-077598","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2023-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.126299+00:00","generated_at":"2026-06-13T13:05:05.363149+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Marker Therapeutics CAO departs; appoints Eliot Lurier as Interim CFO","bullets":["Michael Loiacono, Chief Accounting Officer, separated effective June 30, 2023.","Company agreed to provide severance benefits consistent with employment agreement upon execution of release.","Eliot M. Lurier appointed Interim CFO effective June 30; serves via Danforth Advisors consulting agreement.","Mr. Lurier, age 65, has served as consultant to life science companies through Danforth since July 2021.","No family relationships or material transactions between Lurier and company officers/directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-077598","json":"https://secwatch.observer/filing/0001104659-23-077598.json","markdown":"https://secwatch.observer/filing/0001104659-23-077598.md","text":"https://secwatch.observer/filing/0001104659-23-077598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923077598/0001104659-23-077598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923077598/tm2319618d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T13:05:05.363149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4322b8540","claim":"Michael Loiacono departed as Chief Accounting Officer at Marker Therapeutics, Inc..","evidence_excerpt":"Michael Loiacono, the Chief Accounting Officer of Marker Therapeutics, Inc. (the “ Company ”), was separated from the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923077598/0001104659-23-077598-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"df959ce104","claim":"Eliot M. Lurier was appointed as Interim Chief Financial Officer at Marker Therapeutics, Inc..","evidence_excerpt":"the Company appointed Eliot M. Lurier as the Company’s Interim Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923077598/0001104659-23-077598-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}